UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictors of switching antipsychotic medications in the treatment of schizophrenia

BMC psychiatry, 2010-09, Vol.10 (1), p.75-75, Article 75

2010

Volltextzugriff (PDF)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

BMC psychiatry, 2009-09, Vol.9 (1), p.54-54, Article 54

2009

Volltextzugriff (PDF)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

BMC psychiatry, 2010-01, Vol.10 (1), p.11-11, Article 11

2010

Volltextzugriff (PDF)

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Headache, 2018-09, Vol.58 (8), p.1225-1235

2018

Volltextzugriff (PDF)

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Journal of managed care & specialty pharmacy, 2019-01, Vol.25 (1), p.46-59

2019

Volltextzugriff (PDF)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

BMC medical research methodology, 2012-09, Vol.12 (1), p.142-142, Article 142

2012

Volltextzugriff (PDF)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

BMC psychiatry, 2011-09, Vol.11 (1), p.152-152, Article 152

2011

Volltextzugriff (PDF)

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Headache, 2017-10, Vol.57 (9), p.1359-1374

2017

Volltextzugriff (PDF)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1163-1171

2008

Volltextzugriff (PDF)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Cost effectiveness and resource allocation, 2009-05, Vol.7 (11), p.11-11

2009

Volltextzugriff (PDF)

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Journal of managed care & specialty pharmacy, 2018-09, Vol.24 (9), p.921-928

2018

Volltextzugriff (PDF)

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

CNS neuroscience & therapeutics, 2016-12, Vol.22 (12), p.970-978

2016

Volltextzugriff (PDF)

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Clinical schizophrenia & related psychoses, 2014-07, Vol.8 (2), p.84-90A

2014

Volltextzugriff (PDF)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Patient preference and adherence, 2011-01, Vol.5 (default), p.547-554

2011

Volltextzugriff (PDF)

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Journal of clinical psychopharmacology, 2006-12, Vol.26 (6), p.666-667

2006

Volltextzugriff (PDF)

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Value in health, 2006-03, Vol.9 (2), p.77-89

2006

Volltextzugriff (PDF)

Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia

Clinical schizophrenia & related psychoses, 2008-10, Vol.2 (3), p.226-234

2008

Volltextzugriff (PDF)

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Journal of endourology, 1998-10, Vol.12 (5), p.469-475

1998

Volltextzugriff (PDF)

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Value in health, 2006-09, Vol.9 (5), p.358-358

2006

Volltextzugriff (PDF)

Outcomes of American Lung Association-Indiana Lung Centers asthma program

Disease management, 2005-10, Vol.8 (5), p.311-318

2005

Volltextzugriff (PDF)

The learning curve and the cost of heart transplantation

Health services research, 1992-06, Vol.27 (2), p.219-238

1992

Volltextzugriff (PDF)

Residents' perception of their skill levels in the clinical management of adolescent health problems

Journal of adolescent health care, 1987-09, Vol.8 (5), p.413-418

1987

Volltextzugriff (PDF)

Financial Management Series: Reducing the Costs of Patient Transfers

The Journal of nursing administration, 1987-08, Vol.17 (7/8), p.11-17

1987

Volltextzugriff (PDF)

Reducing the costs of patient transfers

The Journal of nursing administration, 1987-07, Vol.17 (7-8), p.11-19

1987

Volltextzugriff (PDF)

Reducing the Costs of Patient Transfers

The Journal of nursing administration, 1987-07, Vol.17 (78), p.11-19

1987

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Female
(15)
Male
(15)
Adult
(14)
Antipsychotic Agents - Therapeutic Use
(9)
Middle Aged
(9)
Schizophrenia
(9)
Schizophrenia - Drug Therapy
(8)
Treatment Outcome
(7)
Adolescent
(6)
Psychiatry
(6)
Health Care Sciences & Services
(5)
Aged
(4)
Antipsychotic Agents - Economics
(4)
Benzodiazepines - Therapeutic Use
(4)
Cost-Benefit Analysis
(4)
Follow-Up Studies
(4)
Health Care Costs - Statistics & Numerical Data
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Outcomes of American Lung Association-Indiana Lung Centers asthma program

The learning curve and the cost of heart transplantation

Residents' perception of their skill levels in the clinical management of adolescent health problems

Financial Management Series: Reducing the Costs of Patient Transfers

Reducing the costs of patient transfers

Reducing the Costs of Patient Transfers

Aktive Filter

Suchergebnisse filtern